Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...